DJIA 17,826.30 -279.47 -1.54%
NASDAQ 4,931.82 -75.98 -1.52%
S&P 500 2,081.18 -23.81 -1.13%
market minute promo

Alkermes, Inc. (NASDAQ: ALKS)

62.79 -0.89 (-1.40%)

REAL-TIME: Last trade at


company name or ticker

Recent Quotes

ALKS $62.79 -1.40%
1D 1W 3M 6M 1Y 2Y 3Y
Today's Open $63.09
Previous Close $63.68
Daily Range $62.09 - $63.90
52-Week Range $38.49 - $75.17
Market Cap $9.3B
P/E Ratio -303.24
Dividend (Yield) $0.00 (0.0%)
Volume 1,603,797
Average Daily Volume 1,425,775
Current FY EPS -$1.03

Sector

Healthcare

Industry

Drug Makers

Alkermes, Inc. (ALKS) Description

A biotechnology company that develops innovative medicines designed to yield better therapeutic outcomes and improve the lives of patients with serious disease. Website: http://www.alkermes.com/

News & Commentary

A New Drug Could Halt Weight Gain in Patients Taking These Antipsychotics

Alkermes Plc's ALKS 3831 could help patients that take atypical antidepressants avoid gaining weight.

Alkermes - The Underappreciated Biopharmaceutical

Midday Update: Stocks Holding On To Slim Gains Ahead of Upcoming Earnings Glut

Health Care Sector Update for 04/13/2015: NEOT, AEZS, REPH

The Zacks Analyst Blog Highlights: Alkermes, Regulus, Juno Therapeutics, Targacept and Gilead - Pres

The Zacks Analyst Blog Highlights: Alkermes, Regulus, Juno Therapeutics, Targacept and Gilead - Press Releases

Biotech Stock Roundup: Alkermes Drug Fares Well, Targacept Slides on Deal Termination - Analyst Blo

Biotech Stock Roundup: Alkermes Drug Fares Well, Targacept Slides on Deal Termination - Analyst Blog

Alkermes Reports Encouraging Data on Schizophrenia Drug - Analyst Blog

Biogen/AbbVie's MS Drug Zinbryta Under Review in the EU - Analyst Blog

Alkermes 'Taking A Pause,' Citi Says

Top Analyst Upgrades and Downgrades: Cisco, EMC, GameStop, Novavax, Tesla, Yahoo and More

See More ALKS News...

ALKS's Top Competitors

ALKS $62.79 (-1.40%)
Current stock: ALKS
GILD $101.38 (-1.90%)
Current stock: GILD
AMGN $163.58 (-1.97%)
Current stock: AMGN
BIIB $419.44 (-2.15%)
Current stock: BIIB